Remdesivir

瑞德西韦

Report date: 2026/04/15 20:02:38
NMEFirst In Class

Base Information

Drug NameRemdesivir
Drug Alias NameCaptisol®-enabled GS 5734伦德西韦RemidiaVekluryCaptisol +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRNA-directed RNA polymerase inhibitorsViral proteins inhibitors
TargetsRNA-directed RNA polymeraseViral proteins
Therapy Area/IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Autoimmune Diseases +[8] 
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2020/05/07
Country/TerritoryBelgiumUnited StatesSingapore +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Penta Global Foundation Pte LtdGilead Sciences Inc +[6] 
Inactive CompaniesUniversity Of Southern CaliforniaCapital Medical UniversityNational Institute Of Allergy And Infectious Diseases (Niaid) +[6] 
Active IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Autoimmune Diseases +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeJ05AB
Related LinksWikipediaDrugBankKEGG